Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

Bibliography

• Garner RC. Accelerator mass spectrometry in pharmaceutical research and development – a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000;1(2):205-13
   PubMed Web of Science ®Google Scholar
• Bennett CL, Beukens RP, Clover MR, et al. Purser, radiocarbon dating with electrostatic accelerators: dating of milligram samples. Science 1978;201(4353):345-7
   PubMed Web of Science ®Google Scholar
• Nelson DE, Korteling RG, Stott WR. Carbon-14: direct detection at natural concentrations. Science 1977;198:507-8
   PubMed Web of Science ®Google Scholar
• Salehpour M, Possnert G, Bryhni H. Zeptomole sensitivity in biological accelerator mass spectrometry. Anal Biochem 2008;80(10):3515-21
   Google Scholar
• Lappin G, Garner RC. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Wilson I, editor, Handbook of analytical separations. Elsevier: Amsterdam; 2003. p. 331-49
   Google Scholar
• Lappin G. Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Biochem 2004;378(2):356-64
   Google Scholar
• Whitby B. Quantitative whole body autoradiography. In: Lappin G, Temple S, editors, Radiotracers in drug development. Taylor & Francis, CRC Press: Florida, USA; 2006
   Google Scholar
• Beumer JH, Garner RC, Cohen MB, et al. Schellens, human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 2007;25(4):327-34
   PubMed Web of Science ®Google Scholar
• Klem B, Lappin G, Nicholson S, et al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J Clin Pharmacol 2006;46:456-60
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metab Toxicol 2005;1(1):23-32
   PubMedGoogle Scholar
• Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr Pharm Des 2000;6(10):991-1007
   PubMed Web of Science ®Google Scholar
• Young G, Ellis W, Ayrton J, et al. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001;31(8-9):619-32
   PubMed Web of Science ®Google Scholar
• Young G, Ellis WJ. AMS in drug development at GSK. Nucl Instr Methods Phys Res 2007;B(259):752-7
   Google Scholar
• Lappin G, Temple S. Radiotracers in drug development. Taylor & Francis, CRC Press; 2006
   Google Scholar
• Lappin G, Garner RC. A review of human phase 0 and microdosing clinical trials following the US food and drug administration exploratory investigational new drug studies guidance. In J Pharm Med 2006;30(3):159-65
   Google Scholar
• Garner RC, Lappin G. The phase 0 microdosing concept. Br J Clin Pharmacol 2006;61(4):367-70
   PubMed Web of Science ®Google Scholar
• EMEA, Position paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper CPMP/SWP/2599; 23 June 2004
   Google Scholar
• Food and Drug Administration US Department of Health and Human Services Guidance for Industry Investigators and Reviewers. Exploratory IND Studies. January 2006
   Google Scholar
• Combes RD, Berridge T, Connelly J, et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 2003;19(1):1-11
   PubMed Web of Science ®Google Scholar
• Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008;11(1):104-10
   PubMed Web of Science ®Google Scholar
• Garner RC. Less is more: the human microdosing concept. Drug Discov Today 2005;10(7):449-51
   PubMed Web of Science ®Google Scholar
• Buchan P. Smarter candidate selection – utilizing microdosing in exploratory clinical studies. Ernst Schering Res Found Workshop 2007;59:7-27
   PubMedGoogle Scholar
• Zanni GR, Wick JY. Microdosing: the new pharmacokinetic paradigm? Consult Pharm 2006;21(10):756-76
   PubMedGoogle Scholar
• Garner RC. Less is more: the human microdosing concept. Drug Discov Today 2005:449-51
   PubMed Web of Science ®Google Scholar
• Sudo K. Microdosing for reduction of the time and resource for drug development. Drug Metab Pharmacokinet 2007;22(5):327
   Google Scholar
• Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to phase 0 trials. Br J Cancer 2007;97:577-81
   PubMed Web of Science ®Google Scholar
• Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin Cancer Res 2007;13(14):4033-4
   PubMed Web of Science ®Google Scholar
• Robinson WT. Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin Pharmacol Ther 2008;83(2):358-60
   PubMed Web of Science ®Google Scholar
• Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. Drugs R D 2008;9(2):73-81
   PubMedGoogle Scholar
• Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 2007;97(5):577-81
   PubMed Web of Science ®Google Scholar
• Sudo K. Microdosing for reduction of the time and resources for drug development. Drug Metab Pharmacokinet 2007;22(5):327
   PubMed Web of Science ®Google Scholar
• Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006;34(3):384-8
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80(3):203-15
   PubMed Web of Science ®Google Scholar
• Yamane N, Tozuka Z, Sugiyama Y, et al. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;858(1-2):118-28
   PubMed Web of Science ®Google Scholar
• Ni J, Ouyang H, Aiello M, et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 2008;25(7):1572-82
   PubMed Web of Science ®Google Scholar
• Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81(1):24-6
   PubMed Web of Science ®Google Scholar
• Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007;47(12):1595-6; author reply 1597-8
   PubMed Web of Science ®Google Scholar
• Ndovi TT, Cao YJ, Fuchs E, et al. Food affects zidovudine concentration independent of effects on gastrointestinal absorption. J Clin Pharmacol 2007;47(11):1366-73
   PubMed Web of Science ®Google Scholar
• Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2006;2(3):419-27
   PubMed Web of Science ®Google Scholar
• Wong BK, Bruhin PJ, Lin JH. Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys. J Pharm Sci 1999;88(2):277-80
   PubMed Web of Science ®Google Scholar
• Browne TR. Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin Pharmacokinet 1990;18(6):423-33
   PubMed Web of Science ®Google Scholar
• Rubin GM, Waschek JA, Pond SM, et al. Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism. J Pharmacokinet Biopharm 1987;15(6):615-31
   PubMedGoogle Scholar
• Lima JJ, Haughey DB, Leier CV. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide. J Pharmacokinet Biopharm 1984;12(3):289-313
   PubMedGoogle Scholar
• Sarapa N, Hsyu PH, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 2005;45(10):1198-205
   PubMed Web of Science ®Google Scholar
• European Microdosing AMS Parnership Programme. Linear pharmacokinetics demonstrated between a microdose and therapeutic dose of the Pgp substrate fexofenadine in humans, in American Society for Clinical Pharmacology and Therapeutics. Florida, USA; 2008
   Google Scholar
• Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33(7):963-8
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fuse K, Okudaira K, et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005;33(10):1477-81
   PubMed Web of Science ®Google Scholar
• Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004;58(6):601-8
   PubMed Web of Science ®Google Scholar
• Liberman R, Skipper PL, Prakash C, et al. BEAMS Lab: novel approaches to finding a balance between throughput and sensitivity. Nucl Instr Methods Phys Res 2007;259:773-83
   Google Scholar
• Liberman RG, Tannenbaum SR, Hughey BJ, et al. An interface for direct analysis of 14;c in nonvolatile samples by accelerator mass spectrometry. Anal Chem 2004;76(2):328-34
   PubMed Web of Science ®Google Scholar
• Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal Biochem 2008;378:93-5
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration US Department of Health and Human Services Guidance for Industry Safety Testing of Drug Metabolites, February 2008
   Google Scholar
• Miller AK, Adir J, Vestal RE. Excretion of tolbutamide metabolites in young and old subjects. Eur J Clin Pharmacol 1990;38(5):523-4
   PubMed Web of Science ®Google Scholar
• Bateman KP, Castro-Perez J, Wrona M, et al. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 2007;21(9):1485-96
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Garner C. Application of AMS for Human ADME. Drug Metab Rev 2001;33(1):121
   Google Scholar
• Schmid J, Busch U, Trummlitz G, et al. Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotica 1995;25(11):1219-36
   PubMed Web of Science ®Google Scholar